AF Symposium 2025 Late-Breaking Science Collection
Published: 20 January 2025
-
Views:
2093
-
Likes:
7
-
Views:
2093
-
Likes:
7
-
Up Next
-
3m 3sPart 1 | Session 2 Balloon-Based PFA for De Novo PVI in PAF and PersAF
-
2m 57sPart 1 | Session 3 AdmIRE: Predicting Recurrent Atrial Arrhythmias
-
12m 52sPart 1 | Session 4 MANIFEST-REDO: Re-Do Procedures After PFA for AF
-
7m 16s
-
6m 24sPart 2 | Session 1 4 Trials That Will Change My Practice With Dr Luigi Di Biase
-
3m 5sPart 2 | Session 2 Highlights with Dr Ronghua Yang
Overview
Stay up to date with our video collection covering late-breaking data from AF Symposium 2025 in Boston. Don't miss our short, accessible Expert Interviews and Highlights of the most pertinent trials.
More from this programme
Part 1
Expert Interviews
Part 2
Highlights
About the episode
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.
Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and sequential cohorts of the OPTION trial comparing LAA closure with the WATCHMAN FLX device verses oral anticoagulation. The primary safety endpoint was non–procedure-related major bleeding or clinically relevant nonmajor bleeding. The primary efficacy endpoint was a composite of all-cause mortality, stroke, or systemic embolism.
Findings showed that in the concomitant and sequential cohorts, the three-year efficacy outcomes were similar in both treatment arms, whilst the safety outcomes revealed that LAAC with the WATCHMAN FLX device reduced non-procedural bleeding outcomes compared to oral anticoagulation.
Interview Questions:
1. Could you give a brief summary of the trial and the reasoning behind it?
2. What was the patient population and study design?
3. What are the key findings?
4. How should these findings impact patient treatment?
Recorded on-site at AF Symposium in Boston, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles, David Ben-Harosh
Interviewer: David Ramsey
Support: This is an independent interview produced by Arrhythmia Academy.
Faculty Biographies

Walid Saliba
Cardiologist
Dr Walid Saliba is a Cardiologist in the Department of Cardiovascular Medicine at the Cleveland Clinic in Ohio. At the same institution he serves as the director of the Atrial Fibrillation Center and Director of the Electrophysiology Lab.
Dr Saliba achieved both his Physics and Medical Degree at the American University of Beirut. Following his university education, he completed a Cardiology Fellowship at Baylor College of Medicine and an Electrophysiology Fellowship at Cleveland Clinic. He is now board certified in Clinical Cardiac Electrophysiology.
Dr Saliba's clinical interests include the diagnosis and treatment of arrhythmias, catheter ablation, pacemaker and defibrillator implantation, left atrial appendage occlusion, and lead extraction.
He has written numerous publications in respected journals such as Circulation and Journal of the American College of Cardiology, and he has also spoken at…
Comments